Barclays’s Lipocine LPCN Stock Holding History
Bought
Maintained
Sold
Other funds holding LPCN
IC
SCM
EP
RA
VCM
ACM
SC
BFM
SFCM
BC
Barclays's LPCN Position: Q1 2026 in Review
Barclays opened a new position in Lipocine (LPCN) in Q1 2026: 9,412 shares worth $75.2K. The stake represents ﹤0.01% of the portfolio and ranks #4147 among its holdings. This is a return to the name: Barclays previously reported a position in LPCN as recently as Q3 2025.
Barclays first reported a position in LPCN in Q2 2016 and has held it in 17 quarters since. The position peaked at $140K in Q2 2017. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.
- Barclays held 9,412 shares of Lipocine worth $75.2K as of Q1 2026.
- Lipocine was a new Barclays position in Q1 2026.
- Lipocine made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4147 holding.
- Barclays first reported a position in Lipocine in Q2 2016 and has held it in 17 quarters since.
- Barclays's Lipocine position peaked at $140K in Q2 2017.
- 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.